Colin F. Spraggs - Concepedia

Author

Colin F. Spraggs

Also Known As

C F Spraggs, C Spraggs, C. F. SPRAGGS, C. F. Spraggs, C. Spraggs, C.F. SPRAGGS, C.F. Spraggs, COLIN F. SPRAGGS, Colin F Spraggs, Colin F. Spraggs

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United Kingdom)Research Triangle Park Foundation GlaxoSmithKline (United States)University of Hertfordshire Age UK

About

Colin F. Spraggs is an author at GlaxoSmithKline (United Kingdom) specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	474
2	Anesthesia	2	2	183
3	Health Sciences	1	1	16
4	Public Health	1	1	89
5	Biochemistry	1	1	36

Colin F. Spraggs

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
<i>HLA-DQA1</i> * <i>02:01</i> Is a Major Risk Factor for Lapatinib-Induced Hepatotoxicity in Women With Advanced Breast Cancer Colin F. Spraggs, L. R. Budde, Linda P. Briley, Journal of Clinical Oncology	2011	274
Antiemetic activity of the NK1 receptor antagonist GR205171 in the treatment of established postoperative nausea and vomiting after major gynaecological surgery Pierre Diemunsch, P. Schoeffler, B. Bryssine, British Journal of Anaesthesia Major Gynaecological SurgeryGynecologic SurgeryAntiemetic ActivityGastrointestinal PharmacologyGastroenterology	1999	167
Pazopanib Efficacy in Renal Cell Carcinoma: Evidence for Predictive Genetic Markers in Angiogenesis-Related and Exposure-Related Genes Chun‐Fang Xu, Nan Bing, Howard Ball, Journal of Clinical Oncology	2011	148
Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism Chun‐Fang Xu, Brian H. Reck, Zhengyu Xue, British Journal of Cancer	2010	119
<i>HLA-B</i> *57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer Chun‐Fang Xu, Toby Johnson, Xiaojing Wang, Clinical Cancer Research	2015	95
Potential Impact of Adding Genetic Markers to Clinical Parameters in Predicting Prostate Biopsy Outcomes in Men Following an Initial Negative Biopsy: Findings from the REDUCE Trial A. Karim Kader, Jielin Sun, Brian H. Reck, European Urology Potential ImpactGenetic TestingUrologyInitial Negative BiopsyGenitourinary Cancer	2012	89
Prospective Validation of <i>HLA-DRB1</i>*<i>07:01</i> Allele Carriage As a Predictive Risk Factor for Lapatinib-Induced Liver Injury Daniel J. Schaid, Colin F. Spraggs, Shannon K. McDonnell, Journal of Clinical Oncology	2014	75
Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01 Laura R. Parham, Linda P. Briley, L Li, The Pharmacogenomics Journal	2015	60
Lapatinib-Induced Liver Injury Characterized by Class II HLA and Gilbert's Syndrome Genotypes Colin F. Spraggs, Laura R. Parham, Christine M. Hunt, Clinical Pharmacology & Therapeutics	2012	50
Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma Chun‐Fang Xu, Brian H. Reck, Vicki Goodman, Journal of Hepatology UrologyOncogenic AgentMedicineMalignant Blood DisorderRenal Pathology	2010	50

Page 1